图书简介
Translational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders.
Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmcodynamic measures in both animals and humans.
1. Experimental medicine approaches in CNS drug development 2. Modeling and Simulation in the Translational Pharmacology of CNS Drugs 3. Proof-of-mechanism and proof-of-principle trials in early clinical drug development: Applications of biomarkers and experimental medicine 4. Phase I Trials: From Traditional to Newer Approaches 5. De-risking proof-of-concept CNS clinical trials based on translational medicine approaches: What is needed, what we do and what we do not do 6. Biomarker Opportunities to Enrich Clinical Trial Populations for Drug Development in Schizophrenia and Depression 7. Applications of translational neuroimaging research in CNS drug development 8. Assessments of neurotransmitter function by molecular imaging: A translational medicine approach for CNS drug development 9. Applications of neurochemical biomarkers in CNS drug development 10. Applications of neurophysiological biomarkers in CNS drugs 11. Applications of pharmacogenetic and pharmacogenomic biomarkers in CNS drug development 12. Applications of clinical biomarkers in CNS drug development 13. Uses of Stable Isotope Labeling Kinetics in CNS Translational Medicine 14. Multiparameter PKPD Assessment to Quantify Target Engagement in CNS Translational Medicine 15. The Use of Small Exploratory POC Trials to Identify Indications for CNS Drugs 16. Lessons learned from public private partnerships and consortia: The ADNI paradigm 17. Regulatory perspectives on the use of biomarkers and personalized medicine in CNS drug development: The FDA viewpoint 18. Regulatory perspectives on the use of biomarkers and personalized medicine in CNS drug development: The EMA viewpoint 19. Regulatory Qualification of Biomarkers: Learnings from Critical Path Institute 20. Uptake and utilization of biomarkers and personalized medicine by prescribers, payers and patients: Emerging trends 21. Digital health-based biomarkers for use in clinical drug development 22. Translational medicine strategies in drug development for neurocognitive disorders 23. Translational medicine strategies in drug development for neurodegenerative disorders 24. Translational medicine strategies in drug development for neurodevelopmental disorders 25. Translational medicine strategies in drug development for impulse control disorders 26. Translational medicine strategies in drug development for affective disorders 27. Translational medicine strategies in drug development for movement disorders 28. Translational medicine strategies in Alzheimer’s disease drug development 29. Translational medicine strategies in schizophrenia drug development 30. Translational medicine strategies in major depressive disorder drug development 31. Experimental medicine approaches to drug development in anxiety disorders 32. Experimental medicine approaches to drug development in PTSD 33. Translating Neurobiology into Practice in Tobacco, Alcohol, Drug, and Behavioral Addictions 34. Translational medicine strategies in neuropathic pain and chronic pain drug development 35. Use of translational medicine approaches across neuropsychiatric indications: Are we there yet? 36. Hypothesizing Major Depression as a Subset of Reward Deficiency Syndrome (RDS) linked to Polymorphic Reward Genes 37. Translating nonclinical models of disease and drug action to the clinic 38. Heart Rate Variability as a Translational Biomarker for Emotional and Cognitive Deficits
Trade Policy 买家须知
- 关于产品：
- ● 正版保障：本网站隶属于中国国际图书贸易集团公司，确保所有图书都是100%正版。
- ● 环保纸张：进口图书大多使用的都是环保轻型张，颜色偏黄，重量比较轻。
- ● 毛边版：即书翻页的地方，故意做成了参差不齐的样子，一般为精装版，更具收藏价值。
关于退换货：- 由于预订产品的特殊性，采购订单正式发订后，买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性，发生以下情况的，请直接拒收货物，由快递返回：
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全（例如：光盘等）
并请在工作日通过电话400-008-1110联系我们。
- 签收后，如发生以下情况，请在签收后的5个工作日内联系客服办理退换货：
- ● 缺页/错页/错印/脱线
关于发货时间：- 一般情况下：
- ●【现货】 下单后48小时内由北京（库房）发出快递。
- ●【预订】【预售】下单后国外发货，到货时间预计5-8周左右，店铺默认中通快递，如需顺丰快递邮费到付。
- ● 需要开具发票的客户，发货时间可能在上述基础上再延后1-2个工作日（紧急发票需求，请联系010-68433105/3213）；
- ● 如遇其他特殊原因，对发货时间有影响的，我们会第一时间在网站公告，敬请留意。
关于到货时间：- 由于进口图书入境入库后，都是委托第三方快递发货，所以我们只能保证在规定时间内发出，但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间：- 010-68433105/3213正常接听咨询电话的时间为：周一至周五上午8：30～下午5：00，周六、日及法定节假日休息，将无法接听来电，敬请谅解。
- 其它时间您也可以通过邮件联系我们：customer@readgo.cn,工作日会优先处理。
关于快递：- ● 已付款订单：主要由中通、宅急送负责派送，订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐
